Wall Street analysts expect that Humana Inc (NYSE:HUM) will report earnings of $4.60 per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Humana’s earnings. The highest EPS estimate is $5.14 and the lowest is $4.42. Humana reported earnings per share of $4.48 in the same quarter last year, which suggests a positive year-over-year growth rate of 2.7%. The company is expected to report its next earnings report on Wednesday, May 6th.

According to Zacks, analysts expect that Humana will report full-year earnings of $18.64 per share for the current year, with EPS estimates ranging from $18.52 to $18.77. For the next financial year, analysts expect that the company will post earnings of $22.06 per share, with EPS estimates ranging from $21.47 to $22.88. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Humana.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 5th. The insurance provider reported $2.28 EPS for the quarter, beating the Zacks’ consensus estimate of $2.20 by $0.08. Humana had a net margin of 4.17% and a return on equity of 20.89%. The business had revenue of $16.30 billion during the quarter, compared to analyst estimates of $16.15 billion. During the same quarter in the prior year, the business earned $2.65 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis.

Several analysts have recently weighed in on HUM shares. Wells Fargo & Co reaffirmed an “overweight” rating and set a $400.00 price objective (up previously from $338.00) on shares of Humana in a report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price target on shares of Humana from $437.00 to $448.00 and gave the company an “overweight” rating in a research note on Friday, January 3rd. UBS Group increased their price target on shares of Humana from $321.00 to $406.00 and gave the company a “neutral” rating in a research note on Thursday, January 23rd. Barclays increased their price target on shares of Humana from $327.00 to $358.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Finally, Morgan Stanley raised their price objective on shares of Humana from $457.00 to $460.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $380.50.

NYSE:HUM traded down $4.35 during mid-day trading on Friday, hitting $375.85. The company’s stock had a trading volume of 837,245 shares, compared to its average volume of 1,101,424. Humana has a fifty-two week low of $225.65 and a fifty-two week high of $381.04. The company has a current ratio of 1.82, a quick ratio of 1.83 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $46.75 billion, a price-to-earnings ratio of 18.72, a P/E/G ratio of 1.41 and a beta of 0.95. The stock has a fifty day moving average of $360.28 and a 200-day moving average of $316.11.

In other news, insider Timothy Alan Wheatley sold 15,019 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total value of $5,184,708.99. Also, Director James J. /Ky Obrien sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total transaction of $863,025.00. Insiders have sold a total of 45,294 shares of company stock valued at $15,894,412 in the last ninety days. 0.54% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in HUM. Pacer Advisors Inc. increased its position in Humana by 11.8% during the 3rd quarter. Pacer Advisors Inc. now owns 15,420 shares of the insurance provider’s stock worth $3,942,000 after purchasing an additional 1,633 shares in the last quarter. Rothschild Investment Corp IL acquired a new position in Humana during the 3rd quarter worth approximately $243,000. NuWave Investment Management LLC increased its position in Humana by 819.0% during the 3rd quarter. NuWave Investment Management LLC now owns 193 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 172 shares in the last quarter. Sonora Investment Management LLC increased its position in Humana by 9.6% during the 3rd quarter. Sonora Investment Management LLC now owns 572 shares of the insurance provider’s stock worth $146,000 after purchasing an additional 50 shares in the last quarter. Finally, Wealthfront Advisers LLC increased its position in Humana by 3.1% during the 3rd quarter. Wealthfront Advisers LLC now owns 3,486 shares of the insurance provider’s stock worth $891,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 94.44% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.